Perjeta-Herceptin Combo Shows 10-Year Survival, First-Line Prostate Therapy Underused, Recursion Refocuses AI Pipeline
Published about 1 month ago • 1 min read
Superior First-Line Prostate Cancer Treatment Underused Due to Low Awareness
Context: Treatment intensification in metastatic hormone-sensitive prostate cancer has been shown to improve survival, yet implementation remains inconsistent.
What's New? A recent study highlights that many patients are not receiving optimal first-line regimens such as novel hormonal therapies or chemotherapy, primarily due to lack of clinician awareness or familiarity with evolving guidelines.
Why it Matters? Addressing this knowledge gap could improve patient outcomes and reduce disparities in care across urology and oncology practices.
Read More
|
Roche Highlights 10-Year Survival With Perjeta-Herceptin Combo in Breast Cancer
Context: HER2-positive breast cancer has seen dramatic advances with dual antibody therapy, particularly in the adjuvant setting.
What's New? Roche spotlighted long-term follow-up data from the APHINITY trial, showing that Perjeta plus Herceptin and chemotherapy achieved a 94.5% overall survival rate at 10 years in node-negative patients and continued benefit in node-positive disease.
Why it Matters? These data reinforce the durable benefits of dual HER2-targeted therapy and support ongoing use as a standard in early-stage high-risk breast cancer.
Read More
|
Recursion Reworks Pipeline Months After Exscientia AI Merger
Context: AI-driven drug discovery companies are refining their strategies amid market pressures and evolving partnership models.
What's New? Recursion is shifting focus after merging with Exscientia, cutting four internal programs and redirecting resources toward partnered projects with Roche and Bayer. The move reflects a focus on commercially viable and clinically differentiated assets.
Why it Matters? This transition signals a maturing AI drug discovery sector, with companies seeking to balance innovation with tangible clinical outcomes and economic sustainability.
Read More
|
On-Site Dual-Targeted CAR-T Therapy Shows Potential in Mantle Cell Lymphoma
Context: CAR-T therapy for mantle cell lymphoma (MCL) is effective but limited by centralized manufacturing and long turnaround times.
What's New? A dual-targeted, point-of-care manufactured CAR-T cell therapy showed high response rates in MCL with short production timelines. The approach targets both CD19 and CD20 to enhance durability and reduce resistance.
Why it Matters? On-site CAR-T could reduce time-to-treatment and broaden access, while dual targeting may improve efficacy in a relapsing and refractory lymphoma subtype.
Read More
|
|
Oncology Hero
Sharing the latest updates in oncology
Read more from Oncology Hero
Regeneron Acquires 23andMe Research Division for $256M in Bankruptcy Auction Context: As 23andMe navigates Chapter 11 proceedings, key assets tied to its vast genomic database and pharma partnerships have drawn industry attention. What's New? Regeneron has secured a $256 million deal to acquire 23andMe’s therapeutics subsidiary, aiming to leverage the platform’s extensive genotypic and phenotypic data to fuel its precision medicine pipeline. Why it Matters? This acquisition gives Regeneron a...
about 1 month ago • 1 min read
Cullinan and Taiho Reveal Positive NSCLC Data Ahead of FDA Filing Context: Cullinan Oncology and Taiho are developing CLN-081, an EGFR exon 20 insertion–targeting therapy for NSCLC—a mutation subtype with limited approved options. What's New? At ASCO, the companies presented data showing a response rate of 41% and a 12.7-month median duration of response for CLN-081. The results are expected to support an FDA submission in the second half of 2024. Why it Matters? These findings position...
about 1 month ago • 1 min read
Roche’s Itovebi Cuts Risk of Death by 33% in HER2-Positive Breast Cancer Context: HER2-positive breast cancer remains an aggressive subtype despite advances in targeted therapies. What's New? In updated data presented at ASCO, Roche’s anti-HER2 therapy Itovebi (trastuzumab duocarmazine) reduced the risk of death by 33% in pretreated HER2-positive breast cancer, significantly improving overall survival compared to standard therapies. Why it Matters? This reinforces Itovebi’s growing role in...
about 1 month ago • 1 min read